Clinical Trials

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05053659 2026-06-05

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

23 enrolled

Lymphoma, Non-Hodgkin

NCT05360160 2026-06-05

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

43 enrolled

Leukemia, Myeloid, Acute

NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

40 enrolled

Phase 1/2 Active not recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT03319901 2026-06-01

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

82 enrolled

Phase 1/2 Not yet recruiting

Leukemia

NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

Leukemia, Myeloid

NCT06445907 2026-05-29

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

17 enrolled

Leukemia, Myeloid, Acute

NCT05157971 2026-05-28

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

24 enrolled

Burkitt Lymphoma

NCT05734495 2026-05-28

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

46 enrolled

Phase 2 Not yet recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07605949 2026-05-27

RAVEN

88 enrolled

Leukemia, Myeloid, Acute

NCT04628026 2026-05-26

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Phase 3 Recruiting

650 enrolled

Leukemia, Myeloid, Acute

NCT06763341 2026-05-22

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

12 enrolled

Leukemia, Myeloid, Acute

NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

508 enrolled

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT03613532 2026-05-20

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03629171 2026-05-20

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute

NCT04774393 2026-05-20

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

84 enrolled

Leukemia, Myeloid, Acute

NCT04802590 2026-05-20

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

210 enrolled

Lymphoma, Mantle-Cell

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT05183035 2026-05-19

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Phase 3 Recruiting

130 enrolled

Leukemia, Myeloid, Acute

NCT05564650 2026-05-19

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Phase 1 Completed

6 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04941716 2026-05-18

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05853965 2026-05-18

BELI(E)VE

45 enrolled

Plasma cell

Multiple Myeloma

NCT06191978 2026-05-15

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

40 enrolled

Leukemia, Myeloid, Acute

NCT04975919 2026-05-14

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Phase 1/2 Terminated

53 enrolled

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04687761 2026-05-13

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Phase 1/2 Completed

113 enrolled

Leukemia, Myeloid, Acute

NCT05401097 2026-05-13

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

125 enrolled

Leukemia, Myeloid, Acute

NCT06635681 2026-05-13

DAV-AML-2024

380 enrolled

Leukemia, Myeloid, Acute

NCT07454226 2026-05-13

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

Phase NA Recruiting

92 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07495631 2026-05-13

Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia

Phase NA Recruiting

43 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04801797 2026-05-12

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

172 enrolled

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07582159 2026-05-12

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

35 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04273139 2026-05-11

Ibrutinib + Venetoclax in Untreated WM

45 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT03824483 2026-05-07

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

230 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04872790 2026-05-06

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT05099471 2026-05-05

VIWA-1

80 enrolled

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT05529069 2026-05-05

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT07374029 2026-05-05

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Leukemia, Myeloid, Acute

NCT06177067 2026-05-04

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

24 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT06390319 2026-05-01

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

100 enrolled

Phase 3 Active not recruiting

Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04608318 2026-04-30

CLL17

897 enrolled

Leukemia, B-Cell

NCT05536349 2026-04-30

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

60 enrolled

Phase 2 Not yet recruiting

Leukemia

NCT07557056 2026-04-29

Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

25 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04898894 2026-04-28

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

37 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT05268003 2026-04-27

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

Phase 2 Terminated

4 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06129734 2026-04-27

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Leukemia, Myeloid, Acute

NCT04435691 2026-04-23

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Phase 1/2 Terminated

110 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT05263284 2026-04-23

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Suspended

Leukemia, Myeloid, Acute

NCT05955261 2026-04-23

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

70 enrolled